RAPAGLAX RAPAGLAX RAPAGLAX RAPAGLAX RAPAGLAX REPAG REPAG REPAG REPAG REPAG RENIDE RENIDE NOVONORM NOVONORM NOVONORM REPAGLIN REPAGLIN RAPTROL RAPTROL RAPTROL REPASCOT REPASCOT REPASCOT NOVIREP NOVIREP LIMZEL

Dose: 0.5 to 2 mg
Single Dose: 1.2 (1.25)
Frequency: 8 hourly
Route: PO
Instructions: Maximum dose: 4 mg.

Dose:
Single Dose:
Frequency:
Route:
Instructions: Not recommended in this age group

Dose:
Single Dose:
Frequency:
Route:
Instructions: Not recommended in this age group

belongs to Piperidinobenzyl. It belongs to Insulin agonist pharmacological group on the basis of mechanism of action and also classified in Antidiabetic Agent pharmacological group.The Molecular Weight of Repaglinide is 452.60.

Repaglinide is contraindicated in conditions like Coma,Diabetic ketoacidosis.

The signs and symptoms that are produced after the acute overdosage of Repaglinide include Nausea, Convulsions, Coma, Seizures, Sweating, Cerebral damage.The symptomatic adverse reactions produced by Repaglinide are more or less tolerable and if they become severe, they can be treated symptomatically, these include Headache, Diarrhea, Anaphylactoid reactions, Constipation, Allergy, Nausea and vomiting, Thrombocytopenia, Chest pain, Bronchitis, Sinusitis, Hypoglycemia.

Repaglinide is primarily indicated in conditions like NIDDM, Type II diabetes mellitus.

Repaglinide is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementAtorvastatinAtorvastatin may increase repaglinide concentrations by decreasing metabolism. CarbamazepineCarbamazepine may decrease the levels/effects of repaglinide.ClarithromycinClarithromycin increases repaglinide AUC by 40%.ErythromycinErythromycin may increase repaglinide concentrations by decreasing metabolism. Estradiol (Valerate)Estradiol (Valerate) may increase repaglinide concentrations. FluconazoleFluconazole may increase the levels/effects of repaglinide.FluvastatinFluvastatin may increase repaglinide concentrations by decreasing metabolism. GemfibrozilGemfibrozil may increase the levels/effects of repaglinide.KetoconazoleKetoconazole may increase the levels/effects of repaglinide.LovastatinLovastatin may increase repaglinide concentrations by decreasing metabolism. NicardipineNicardipine may increase the levels/effects of repaglinide.PhenobarbitonePhenobarbitone may decrease the levels/effects of repaglinide.ProgesteroneProgesterone may increase repaglinide concentrations. RifampicinRifampicin may decrease the levels/effects of repaglinide.VORICONAZOLEVoriconazole may increase the serum concentration of repaglinide by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Abnormal LFTs

Drug should not be given to Pregnant Mothers.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Use with caution in patients with hepatic impairment. All oral hypoglycemic agents are capable of producing hypoglycemia. Proper patient selection, dosage and the instruction to the patients are important to avoid hypoglycemic episodes. It may be necessary to discontinue repaglinide and administer insulin if the patient is exposed to stress (fever, trauma, infection, surgery). At higher dosages sulfonylurea may block the ATP-sensitive potassium channel, which may correspond to an increase risk of cardiovascular events. Avoid the use of sulfonylurea at higher dosages (repaglinide daily doses >1.5 mg).